共查询到19条相似文献,搜索用时 187 毫秒
1.
目的探讨非腺癌前列腺恶性肿瘤的诊断及治疗方法。方法非腺癌前列腺恶性肿瘤19例。年龄2~64岁,平均32岁。病程5d~10年。临床症状以尿道刺激症、排尿困难及会阴部胀痛为主。直肠指诊提示前列腺部位肿瘤。12例血清前列腺特异性抗原、5例酸性磷酸酶检查正常。B超、CT、MRI检查初步诊断为前列腺恶性肿瘤。19例术前均行前列腺穿刺活检术。12例仅行姑息性尿流改道术,7例行根治术,其中6例术后予以放疗和(或)化疗。结果病理报告侵袭性血管纤维瘤病1例、鳞癌2例、平滑肌肉瘤5例、横纹肌肉瘤3例、纤维肉瘤2例、恶性外周性原始神经外胚层肿瘤2例、间叶肉瘤3例、恶性间质瘤1例。12例行姑息性尿流改道术者术后15个月内因肿瘤全身转移死亡,5例行根治术的患者生存15~26个月后死于肿瘤全身转移,1例恶性间质瘤患者根治术后辅以化疗已生存13个月,1例间叶肉瘤行根治性膀胱前列腺全切加回肠膀胱术,术后予以放疗及化疗,已生存3个月。结论非腺癌前列腺恶性肿瘤患者的临床表现、直肠指诊、B超及CT检查对诊断有重要意义,有效治疗是早期根治术为主的综合治疗。 相似文献
2.
目的 探讨成人肾母细胞瘤的临床特点.方法肾母细胞瘤患者6例.男4例,女2例.年龄21~58岁,平均31岁.临床表现为腰腹痛4例,其中伴肉眼血尿1例,伴发热1例;腰腹部肿块2例.查体腹部能触及肿块者4例,有肾区叩击痛5例,下腹部压痛1例.6例尿常规检查2例红细胞(++).6例B超检查发现5.0 cm×5.0 cm~22.0 cm×25.0 cm的低回声团块,边界尚清.4例CT检查均发现密度不均、边界不清的实质性肿块,其中1例增强后肿物不均匀强化,中心有出血坏死;CT值11~40 HU,平均22.5 HU,增强后CT值35~78 HU,平均63.5 HU.2例MRI检查,提示实性占位性病变.3例IVU检查提示肾影增大,肾盏受压变细,肾盂积水1例.术前诊断肾肿瘤5例、盆腔包块1例.6例均手术治疗.根治性肾切除术5例,卵巢切除术1例,均同时行腹膜后淋巴结清扫术.术中见肿瘤侵犯胰尾1例,侵犯侧腹壁1例,侵犯下腔静脉1例;2例肾门淋巴结>1.5 cm×1.5 cm.剖开肿物见切面灰黄或灰白色,4例包膜完整,3例肿瘤中心出血坏死.术后接受化疗加放疗4例,单纯化疗2例.结果 按美国国家肾母细胞瘤研究组(NWTS)分期:Ⅰ期1例、Ⅱ期2例、Ⅲ期2例、Ⅳ期1例.6例均顺利手术切除肿瘤.肿瘤直径4.5 cm~25.0 cm,平均11.8 cm.术后病理确诊,其中组织学分型显示分化良好型5例,分化不良型1例.有淋巴结转移者2例,局部浸润者3例,肺转移者1例(同时存在局部浸润).术后随访1~7年,平均3.5年.5例无瘤生存,1例术后2年死于肺转移. 结论 成人肾母细胞瘤患者就诊时大多已有肿瘤转移或浸润,发生血行转移者也明显多于其他肾肿瘤,早期诊断、根治性手术及术后放化疗可提高生存率. 相似文献
3.
患者,67岁.血尿1年加重3个月,伴尿频、尿急和尿痛于2004年11月入院.直肠指诊前列腺增大,质韧、边缘清楚、中央沟变浅,未触及结节.直肠指诊后血尿加重.血清PSA 7.24 ng/ml,游离PSA 0.76 ng/ml.超声检查前列腺大小4.6 cm×4.1 cm×4.1 cm,内腺2.4 cm×2.4 cm×2.8 tin,内外腺间见高回声,内腺见低回声结节,膀胱壁左侧见1.1 cm×1.0 cm低回声病变.MRI检查示前列腺外周区增大,呈等T1长T2混杂信号,与膀胱直肠关系密切,直肠间隙存在,精囊无异常. 相似文献
4.
5.
<正>患者,男,62岁,2014年6月因无明显诱因出现"尿频、尿急、排尿困难",就诊于当地医院,检查发现tPSA增高(7.98ng/ml),未行系统诊治。2014年10月初在我院复查tPSA 9.86ng/ml。肛门指诊:前列腺大小约4cm×4cm,两侧叶不对称,右侧叶尖部可触及硬结,无触痛,指套无染血。经直肠前列腺B超检查:前列腺右侧尖部可见一低回声结节。前列腺MRI:前列腺略大,中央腺体增大,其内信号不均,可见多发小结节状等及稍长T1 相似文献
6.
游离PSA与总PSA比值在前列腺癌鉴别诊断中的意义 总被引:6,自引:2,他引:4
目的 探讨游离前列腺特异性抗原 (fPSA)与总前列腺特异性抗原 (tPSA)比值 (f tPSA)在tPSA为 4~ 10ng ml时对前列腺癌和良性前列腺增生 (BPH)鉴别的意义及其局限性。方法 对1998年 10月至 2 0 0 2年 10月接受诊治的 180例血清tPSA为 4~ 10ng ml的前列腺癌和BPH患者进行回顾性分析。经组织学证实 ,36例 (2 0 % )是前列腺癌 ,14 4例 (80 % )是BPH。血清中tPSA和fPSA通过酶免微粒子捕捉法测定。前列腺体积通过经腹壁超声测定。前列腺癌与BPH组间比较用t检验。采用Pearson相关系数分析前列腺体积与f tPSA之间的相关性。结果 前列腺癌患者的tPSA、f tPSA平均值分别是 6 75ng ml与 0 17;BPH患者则是 6 4 8ng ml和 0 2 5。两组患者的tPSA差异无显著意义 (P >0 0 5 ) ,而前列腺癌患者的f tPSA值显著低于BPH患者 (P <0 0 1)。此外 ,两组患者的前列腺体积与f tPSA均呈显著正相关 (前列腺癌组相关系数r=0 5 0 ,P <0 0 1;BPH组r=0 2 4 ,P <0 0 1)。在前列腺体积小于 4 0cm3,两组患者的f tPSA差异有显著意义 (P <0 0 5 ) ,当体积超过 4 0cm3,则差异无显著意义 (P >0 0 5 )。结论 f tPSA对tPSA在 4~ 10ng ml之间的前列腺癌和BPH的鉴别诊断有重要意义 ,但由于受前列腺体积的影响 ,只有在 相似文献
7.
男性后尿道腺瘤诊治24例报告 总被引:1,自引:0,他引:1
2000年6月至2005年1月,我科采用经尿道电切治疗男性后尿道腺瘤患者24例,效果良好.现报告如下.
对象与方法 本组24例.年龄28~76 岁.病程3~10 年.临床表现终末肉眼血尿7例,血尿呈间歇性,色鲜红、量少,尿常规检查红细胞(+)~(++++);间断性血精4例,精液鲜红色、量少,精液检查红细胞(+)~(+++),前列腺液(EPS)常规检查和经直肠精囊、前列腺B超检查正常;尿频、尿急、尿痛8例,EPS检查白细胞(+)~(++++);尿道流血2例;排尿困难伴尿频、尿急3例,B超检查示BPH,最大尿流率5~10 ml/s,剩余尿160~400 ml. 相似文献
8.
成人原发性前列腺肉瘤少见,2 0 0 0年5月至2 0 0 3年4月我院诊治6例。现报告如下。材料与方法 本组6例。年龄2 7~77岁,平均5 1岁。占同期收治前列腺恶性肿瘤(89例)的6 .7%。病史2周~12个月。以排尿困难为首发症状2例;以排便困难为首发症状3例,伴排尿困难2例;因体检发现盆腔肿物1例。肿瘤大小6 .0cm×7.0cm×9.0cm~11.0cm×12 .0cm×16 .0cm。术前均经前列腺穿刺活检证实为肉瘤,无远处转移病灶。结果 3例术前4~5d经股动脉穿刺、双侧髂内动脉栓塞术,其中1例行双髂内动脉阿霉素10mg灌注。行前列腺、膀胱全切除并尿流改道术5例1例术后病理… 相似文献
9.
膀胱癌术后腹壁切口种植转移的治疗与预后 总被引:7,自引:1,他引:6
目的 总结膀胱部分切除术后腹壁切口种植转移患者的诊治效果。 方法 1985~1999年共收治膀胱癌术后腹壁切口种植转移患者 10例。男 9例 ,女 1例。年龄 39~ 6 8岁。移行细胞癌 6例 ,均为低分化G3 肿瘤 ;移行细胞癌合并鳞癌和腺癌各 1例 ,鳞癌和粘液腺癌各 1例。腹壁转移灶 1.0~ 6 .9cm× 1.4~ 11.5cm。 结果 采用膀胱全切加腹壁转移灶切除 2例 ,经尿道膀胱肿瘤电切术 (TURBT)加腹壁转移灶切除 1例 ,尿流改道加放疗和 (或 )化疗 2例 ,腹壁转移灶切除加放疗和 (或 )化疗 3例 ,单纯放疗和 (或 )化疗 2例。 10例中死亡 7例 ,其中 6例生存 4~ 14个月 ,1例生存4 1个月 ;3例存活者随访 5~ 9个月 ,未见复发。 结论 膀胱癌术后腹壁切口种植转移癌一般分化差 ,或合并其他癌。膀胱全切加肿物切除 ,辅助放化疗虽然能延长患者生存期 ,但预后很差 相似文献
10.
患者,66岁.自诉食欲减退伴消瘦6个月,排尿困难症状进行性加重于2012年3月11日入院.伴有尿频、尿急、尿痛及夜尿增多症状,无尿潴留病史.直肠指检可触及前列腺增大,质地较硬,中央沟消失,左侧可触及结节,无明显压痛.实验室检查:tPSA 1.82μc,fPSA 0.38μg/L,f/t 0.21,睾酮3.78μg/L,细胞角蛋白19片段10.82 μg/L,糖类抗原19~9 679.30 U/ml,铁蛋白413.20μg/L,糖类抗原72~4 11.33 U/ml.泌尿系B超检查:左肾及左输尿管积水,左肾集合系统分离约4.7 cm,左输尿管明显扩张,最宽处约2.0 cm;前列腺体积增大,大小约6.3 cm×6.0 cm×5.0 cm,内可见一低回声包块,边界不清,回声不均质,CDFI可见点条状血流信号,向膀胱三角区及膀胱后壁延续,相应区域膀胱壁明显增厚.下腹部及盆腔增强CT检查:膀胱直肠陷窝内占位,最大截面积5.7 cm×5.0 cm,考虑前列腺癌累及膀胱及精囊;左输尿管中段旁软组织密度影,考虑转移淋巴结;左肾盂及左输尿管明显扩张,左肾皮质变薄.核素全身骨扫描检查:右侧第8、9肋骨局限性骨质代谢异常增强,考虑骨转移瘤.膀胱镜检查见膀胱黏膜光滑平整,三角区明显隆起,高于后唇.行经直肠前列腺穿刺活检术,分别于前列腺左侧叶和右侧叶穿刺8针.术后病理检查镜下见癌细胞具有丰富的泡沫状胞质,染色淡伊红或透亮,胞质内含有空泡,核质比例很小,细胞核小而深浓染,呈圆形,偶见核分裂象.腺体密集聚集呈腺泡样,形成腺体较小,混杂在良性大的腺体之间,基底细胞消失,呈浸润性生长,腺腔内可见深粉染的分泌物.病理组织学诊断:(双侧前列腺)腺癌(泡沫状腺体型),Gleason2+3=5分.免疫组化染色检查:CK7(+),CEA(±),PSA、P504S、34βE12、p63、S-100、CK20(-).术后因患者经济拮据,仅口服比卡鲁胺50mg/d,未进行药物去势及手术治疗.随访1年患者因肿瘤全身转移致多器官衰竭死亡. 相似文献
11.
目的 探讨膀胱小细胞癌的临床及病理特点.方法 回顾性分析9例膀胱小细胞癌的基本资料.男6例,女3例.年龄45~79岁,平均62岁.临床表现为肉眼血尿7例,排尿困难及下腹部疼痛2例.肿瘤直径0.5~7.0 cm,平均2.0 cm;多发2例,单发5例,全膀胱弥漫性生长2例.7例行尿脱落细胞学检查,阳性4例.9例均行手术治疗,其中4例术前诊断为浅表性者行TURBt,术后均定期行吡柔比星膀胱灌注,1例化疗3个周期;膀胱部分切除2例,均定期行吡柔比星膀胱灌注,1例化疗2个周期;根治性膀胱全切3例,静脉化疗2例.结果 术后病理检查:肿瘤细胞体积小,呈圆形,胞质稀少,核浓染,缺乏巢状结构.免疫组化染色:嗜铬素A(+)、神经元特异性烯醇化酶(+).诊断为小细胞癌,其中1例含移行细胞癌成分,1例合并前列腺癌.1例术前检查显示高血钙(3.15 mmol/L)和低血磷(0.61 mmol/L),术后1个月血钙及血磷恢复正常.保留膀胱者随访4例,3例分别于术后4、9、25个月死于转移,1例术后化疗者随访24个月未见复发及转移.膀胱全切3例中2例分别于术后2、28个月死亡,1例术后随访32个月未见肿瘤复发及转移.结论膀胱小细胞癌恶性程度高,预后差,根治性膀胱全切加全身化疗是主要的治疗方法,保留膀胱的手术应配合全身化疗.决定预后的是肿瘤的临床分期及治疗方法.Abstract: Objective To investigate the clinical and pathological features of small cell carcinoma of the urinary bladder. Methods The pathological and clinical data of 9 cases of small cell carcinoma were analyzed retrospectively. There were 6 males and 3 females, ages 45 to 79 years (mean age, 62 years). Clinical manifestations of 7 cases included gross hematuria and dysuria, the other 2 cases experienced lower abdominal pain. The mean tumor size was 2.0 cm (ranged, 0.5 to 7.0 cm). Two cases had multiple tumors and 5 cases had single tumors. The growth pattern in 2 cases was diffuse growth in the whole bladder. In 4 cases tumor cells were found in urine cytology. All 9 patients underwent surgical treatment, including TURBt. Four patients were diagnosed as superficial tumors before operation. All the patients underwent regular theprubicine irrigation in the bladder. One case underwent additional intravenous chemotherapy for 3 cycles. Partial cystectomy was performed in 2 cases, with regular theprubicine irrigation in bladder and 1 case underwent intravenous chemotherapy for 2 cycles. Radical cystectomy was performed in 3 cases, with 2 cases undergoing intravenous chemotherapy after operation. Results Pathological findings showed that tumor cells were small and round in shape. These hyperchromatic nuclei showed limited cytoplasm with lack of nesting characters. CgA and NSE were positive in immunohistochemistry. The final diagnosis was small cell carcinoma, with 1 case accompanied with transitional cell carcinoma and 1 case accompanied with prostate cancer. One case showed high preoperative serum calcium (3.15 mmol/L) and low serum phosphate (0.61 mmol/L), which returned to normal 1 month after operation. Four cases who′s bladder was preserved were followed up, 3 cases were alive for 4, 9 and 25 months after operation. The 1 case who underwent intravenous chemotherapy was followed up for 24 months and there was no sign of relapse or metastasis. In all the 3 cases with radical cystectomy, 2 cases died 2 and 28 months postoperativly. Another case with adjuvant chemotherapy was followed up for 24 months without recurrence or metastasis. Conclusions Small cell carcinoma of the urinary bladder is highly malignant with poor prognosis. Radical cystectomy in combination with systemic chemotherapy has better efficacy. Retained bladder surgery with systemic chemotherapy is an alternative choice. The most important factors which influence the prognosis of the tumor are clinical stage and therapeutic methods. 相似文献
12.
目的:探讨原发灶和所有转移灶同时全覆盖放疗治疗寡转移性去势抵抗性前列腺癌(CRPC)的疗效和毒性反应。方法:回顾性分析北京大学第一医院2011年10月至2017年6月收治的44例寡转移(≤4处转移灶)CRPC患者的临床资料。平均年龄72(57~86)岁,初诊时PSA中位值38.545(6.640~1 066.000)n... 相似文献
13.
OBJECTIVES: To describe the clinical parameters of low PSA, progressive metastatic androgen-independent prostate cancer. METHODS: From April 1995 to May 1999, we selected 18 patients with clinically progressive androgen-independent prostate cancer and low PSA (=10 ng/ml). Patients received cisplatin-based therapy. Specimens from the primary tumor were reviewed and neuroendocrine differentiation was determined with chromogranin-A and neuron-specific enolase immunocytochemical staining. RESULTS: The median initial PSA level was 1.6 ng/ml (0-9.5). Each patient demonstrated elevation of at least one of the following markers: carcinoembryonic antigen, CA 19-9, CA15-3 and CA 125 CA. Metastases involved bone in 11 patients (61.1%) - 5 (27.7%) blastic, 2 (11.1%) lytic, and 4 (22.2%) combined - liver in 10 patients (55.5%), lymph nodes in 8 (44.4%), and lung in 6 (33.3%); solitary sites as orbit, skin and spleen were noted as well. A prostatic pelvic mass was detected in 13 patients (72.2%). Of the 12 patients who consented to chemotherapy, 8 (66.6%) achieved an objective response (95% CI, 34. 8-90%), including 1 patient with complete response. Hematoxylin and eosin evaluation revealed two major groups: neuroendocrine tumors, either pure small cell cancer in 6 patients (37.5%) or combined small cell cancer and adenocarcinoma in 8 (50%), and predominant poorly differentiated prostate cancer in 2 (12.5%). Neuroendocrine immunoreactivity was detected in all the specimens. CONCLUSIONS: Progressive androgen-independent prostate cancer with low serum PSA is characterized by visceral metastases, high proportion of lytic bone disease, sensitivity to cisplatin-based chemotherapy, and histological features of small cell or poorly differentiated prostate cancer. In this subgroup of patients, selection of the therapeutic approach can be based on clinical parameters. The rise of the serum markers may aid in the diagnosis and follow-up of these patients. 相似文献
14.
目的 观察Gleason 10分前列腺癌患者的临床诊疗及疾病变化过程,总结该类前列腺癌患者的临床特点及预后影响因素. 方法 2005年1月至2010年5月,21例初诊为前列腺癌、Gleason 10分、行手术去势加抗雄激素治疗的患者纳入本研究.初诊年龄56~85岁,平均73岁.PSA 8.9~261.0 ng/ml,平均60.8 ng/ml,其中6例PSA≤20 ng/ml.行核素骨扫描发现骨转移16例.予双侧睾丸切除术加氟他胺或比卡鲁胺全雄激素阻断治疗.术后1个月复查PSA,以后每3个月随访PSA.治疗后6个月为单纯内分泌治疗观察终点.6个月内PSA未降至<4 ng/ml且无远处转移者加用局部外放射治疗,伴骨转移者使用基于多西他赛与泼尼松的全身化疗.患者死亡为研究终点.结果 15例初诊PSA> 20 ng/ml患者中,5例治疗后6个月内血清PSA未降至正常水平,其中4例伴骨转移.该4例子全身化疗后PSA均未降至正常水平,3例1年内死亡,1例诊断后19个月死亡,1例疾病局限患者予外放射治疗,PSA下降至正常水平8个月后出现肿瘤进展,诊断后11个月死亡.10例治疗后6个月内血清PSA降至正常水平,其中3例分别于诊断后第19、28、36个月死于肿瘤,7例存活.6例初诊时PSA≤20 ng/ml患者中3例治疗后6个月内PSA未降至正常水平,其中2例伴骨转移予化疗后于1年内死亡;1例PSA下降至正常水平但仍出现肿瘤进展,全身多发骨转移,化疗无效,1年内死亡;1例4年后因前列腺癌死亡;1例随访6个月,PSA降至0.07 ng/ml. 结论 Gleason 10分前列腺癌肿瘤进展迅速,抗雄激素治疗疗效不佳,行伞雄激素阻断后6个月内PSA无法下降至正常水平患者病情进展凶险.初诊PSA≤20 ng/ml且病理证实Gleason 10分者可能预示预后不佳. 相似文献
15.
目的探讨腹膜外途径腹腔镜前列腺癌根治术的临床效果。方法回顾性分析总结2009年5月至2011年7月经腹膜外径路进行腹腔镜前列腺癌根治术患者12例,年龄60~75岁,平均年龄68岁。血清前列腺特异性抗原(prostate specific antigen,PSA)为0.7~23.6ng/ml。TNM分期T1N0M08例,T2N0M03例,T3aN0M01例。所有患者均于术前行前列腺穿刺活组织检查,证实为前列腺癌。结果 12例患者均顺利完成手术,手术时间为130~360min,平均270min;术中出血量为150~900ml,平均390ml,1例患者术中输血。术后病理检查结果显示肿瘤切缘为阳性的2例患者术后加用全雄激素阻断治疗3个月。术后留置尿管时间14~22d,平均18.6d,无直肠损失病例,3例术后出现轻度尿失禁的患者经提肛训练等辅助治疗3个月后好转,能自主排尿。术后3个月时PSA为0.02~0.10ng/ml,术后随访8例,随访时间为3~24个月,未发现肿瘤局部复发和远处转移。结论腹膜外径路腹腔镜前列腺癌根治术视野清晰、创伤小、恢复快,是一种安全、有效的治疗方法,值得临床推广。 相似文献
16.
Sawada A Segawa T Nakanishi S Kinoshita H Yamamoto S Kamoto T Ogawa O 《Hinyokika kiyo. Acta urologica Japonica》2005,51(11):771-773
A 77-year-old man presented with complaints of dysuria, nocturia and painless nodule on his penis. Laboratory examination revealed elevated serum prostate-specific antigen (PSA) and CA19-9. Pathological examinations on prostate and penile biopsy specimens revealed prostate adenocarcinoma with penile metastasis. The patient was diagnosed as having prostate cancer stage D2 (T4N1M1) with bone, lymph node and penile metastases. There was no response to initial hormonal therapy with the surgical castration and diethylstilbestrol. However, decrease of the tumor size, as well as PSA and CA19-9 values were achieved after the combined chemotherapy with Estramustine, Paclitaxel and Carboplatin. 相似文献
17.
目的探讨内镜下钬激光治疗特殊早期上尿路上皮肿瘤的安全性及有效性。方法2002年4月~2010年5月,对10例不适合行根治性。肾输尿管切除术的早期上尿路上皮肿瘤患者行内镜下钬激光治疗,其中输尿管肿瘤7例(1例合并膀胱肿瘤),肾盂肿瘤3例。单发7例,多发3例。术前肿瘤分期cTa~cT1。3例对侧已行肾输尿管全长切除,2例孤立肾,3例肾功能不全,1例2~3级心功能不全,1例肿瘤小(〈1cm,位于。肾盂,单发且表浅)。输尿管硬镜治疗7例,软镜1例,微通道经皮肾镜2例。术后行丝裂霉素上尿路及膀胱灌注化疗。结果10例术后随访2年,无肿瘤死亡。1例术后6个月输尿管狭窄,其余均未出现大出血、严重感染、周围脏器损伤及全身肿瘤转移。复发4例,其中1例输尿管合并膀胱肿瘤者膀胱内复发,1例为肾盂内单发肿瘤复发,2例为输尿管单发肿瘤复发。该4例随访5年,1例未见肿瘤复发与转移,3例复发3—4次,且为尿路多处复发,行肾盂输尿管癌根治术,其中2例术后血液透析1年内肿瘤转移死亡。结论对不适合行根治性肾输尿管切除术的早期上尿路上皮肿瘤,内镜下钬激光治疗短期内是安全有效的。 相似文献
18.
《中华泌尿外科杂志》2009,30(11)
目的 总结经尿道KTP激光前列腺汽化术(PVP)治疗伴有下尿路梗阻晚期前列腺癌的临床疗效.方法 伴有下尿路梗阻的晚期前列腺癌患者33例.年龄(76±6)岁.其中T3 18例,T4 15例.前列腺体积36~140 ml.患者术前IPSS为28.2±3.6,QOL为5.0±0.7,Q_(max) 4.7~10.1 ml/s,残余尿量(RU)为(126.0±25.2)ml.33例均行KTP激光经尿道汽化前列腺治疗.19例初发前列腺癌患者同时行PVP和睾丸切除,14例为睾丸切除和抗雄激素等治疗后仍有明显的排尿梗阻症状,有尿潴留史15例.分别对术前及PVP术后1、6个月患者IPSS、QOL Qmax、血PSA、RU等指标进行统计分析.采用SPSS 13.0软件处理数据,均数间比较采用配对t检验.结果 33例手术经过顺利.28例术后3~4 d拔除导尿管,排尿情况改善明显;5例初次拔管后仍有排尿困难而再次留置导尿,延时拔管后均能自行排尿.术后并发症包括血尿14例、短暂尿失禁3例.术后1个月时IPSS、QOL、Q_(max)、血PSA、RU分别为14.6±2.8、3.1±0.4、(13.2±5.6)ml/s、(16.3±13.4)ng/ml、(24.6±5.9)ml;术后6个月时分别为14.2±3.3、3.4±0.5、(12.2±3.4)ml/s、(8.0±6.5)ng/ml、(31.1±8.7)ml.术后1、6个月的IPSS评分、QOL、Qmax、血PSA与术前比较差异均有统计学意义(P<0.01),术后1、6个月间IPSS评分、QOL、Q_(max)比较差异无统计学意义(P>0.05).结论 PVP可以有效解除前列腺癌患者的下尿路梗阻症状,明显改善患者生活质量.安全、有效. 相似文献
19.
Shichiri Y Egawa S Kamoto T Kakehi Y Ogawa O Yoshida O Sumiyoshi Y Akakura K Arai Y 《Hinyokika kiyo. Acta urologica Japonica》2000,46(11):785-790
The number of cases of stage T1c prostate cancer has dramatically been increasing since the introduction of PSA as a screening test. The patients with T1c prostate cancer are usually treated by radical prostatectomy. In this group, however, some cancers are of small tumor volume and with a Gleason score of less than 7. These cancers are considered to be good candidates for watchful waiting management. We have investigated 40 patients with T1c prostate cancer treated by radical prostatectomy between 1996 and 1998. All 9 patients harboring tumors of Gleason score 7 or greater had tumors larger than 0.5 cm3. We have investigated PSA-related parameters including total PSA (PSA), PSA density (PSAD), free PSA, and % free PSA in 31 patients with T1c cancers of Gleason score 6 or less in order to clarify good preoperative predictors of tumor volume. We compared the distribution of PSA, PSAD, free PSA, and % PSA between the larger and smaller tumor groups. There was no significant difference in PSA, PSAD, or free PSA value. The small tumor group had a greater mean % free PSA than the larger tumor group (23.27 versus 11.88, p = 0.007). Areas under receiver operating characteristic curves were 0.715, 0.794, 0.636, and 0.842 for PSA, PSAD, free PSA and % free PSA. In stage T1c prostate cancer of Gleason score 6 or less, % free PSA may be the most useful preoperative predictor for tumor volume of 0.5 cm3 or greater. 相似文献